- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 27 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.2: 4 residues within 4Å:- Chain A: N.264, S.293, N.448
- Ligands: NAG-NAG-BMA-MAN-MAN.1
No protein-ligand interaction detected (PLIP)NAG-NAG.3: 5 residues within 4Å:- Chain A: N.297, N.333, S.335, N.411, V.446
No protein-ligand interaction detected (PLIP)NAG-NAG.4: 4 residues within 4Å:- Chain A: W.98, N.236, T.238, S.276
No protein-ligand interaction detected (PLIP)NAG-NAG.5: 4 residues within 4Å:- Chain A: R.194, N.199, T.200
- Chain C: R.310
No protein-ligand interaction detected (PLIP)NAG-NAG.6: 5 residues within 4Å:- Chain A: V.136, N.150, Y.167, L.169, D.322
1 PLIP interactions:1 interactions with chain A- Hydrophobic interactions: A:Y.167
NAG-NAG.7: 3 residues within 4Å:- Chain A: N.303, I.324, V.442
No protein-ligand interaction detected (PLIP)NAG-NAG.8: 4 residues within 4Å:- Chain A: E.89, N.90
- Chain B: G.23, S.24
No protein-ligand interaction detected (PLIP)NAG-NAG.9: 3 residues within 4Å:- Chain A: H.87, N.243, V.244
No protein-ligand interaction detected (PLIP)NAG-NAG.10: 5 residues within 4Å:- Chain A: N.297, T.299, H.331, N.333, R.444
No protein-ligand interaction detected (PLIP)NAG-NAG.12: 4 residues within 4Å:- Chain C: N.264, S.293, N.448
- Ligands: NAG-NAG-BMA-MAN-MAN.11
No protein-ligand interaction detected (PLIP)NAG-NAG.13: 5 residues within 4Å:- Chain C: N.297, N.333, S.335, N.411, V.446
No protein-ligand interaction detected (PLIP)NAG-NAG.14: 4 residues within 4Å:- Chain C: W.98, N.236, T.238, S.276
No protein-ligand interaction detected (PLIP)NAG-NAG.15: 4 residues within 4Å:- Chain C: R.194, N.199, T.200
- Chain E: R.310
No protein-ligand interaction detected (PLIP)NAG-NAG.16: 5 residues within 4Å:- Chain C: V.136, N.150, Y.167, L.169, D.322
1 PLIP interactions:1 interactions with chain C- Hydrophobic interactions: C:Y.167
NAG-NAG.17: 3 residues within 4Å:- Chain C: N.303, I.324, V.442
No protein-ligand interaction detected (PLIP)NAG-NAG.18: 4 residues within 4Å:- Chain C: E.89, N.90
- Chain D: G.23, S.24
No protein-ligand interaction detected (PLIP)NAG-NAG.19: 3 residues within 4Å:- Chain C: H.87, N.243, V.244
No protein-ligand interaction detected (PLIP)NAG-NAG.20: 5 residues within 4Å:- Chain C: N.297, T.299, H.331, N.333, R.444
No protein-ligand interaction detected (PLIP)NAG-NAG.22: 4 residues within 4Å:- Chain E: N.264, S.293, N.448
- Ligands: NAG-NAG-BMA-MAN-MAN.21
No protein-ligand interaction detected (PLIP)NAG-NAG.23: 5 residues within 4Å:- Chain E: N.297, N.333, S.335, N.411, V.446
No protein-ligand interaction detected (PLIP)NAG-NAG.24: 4 residues within 4Å:- Chain E: W.98, N.236, T.238, S.276
No protein-ligand interaction detected (PLIP)NAG-NAG.25: 4 residues within 4Å:- Chain A: R.310
- Chain E: R.194, N.199, T.200
No protein-ligand interaction detected (PLIP)NAG-NAG.26: 5 residues within 4Å:- Chain E: V.136, N.150, Y.167, L.169, D.322
1 PLIP interactions:1 interactions with chain E- Hydrophobic interactions: E:Y.167
NAG-NAG.27: 3 residues within 4Å:- Chain E: N.303, I.324, V.442
No protein-ligand interaction detected (PLIP)NAG-NAG.28: 4 residues within 4Å:- Chain E: E.89, N.90
- Chain F: G.23, S.24
No protein-ligand interaction detected (PLIP)NAG-NAG.29: 3 residues within 4Å:- Chain E: H.87, N.243, V.244
No protein-ligand interaction detected (PLIP)NAG-NAG.30: 5 residues within 4Å:- Chain E: N.297, T.299, H.331, N.333, R.444
No protein-ligand interaction detected (PLIP)- 36 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.31: 5 residues within 4Å:- Chain A: S.152, F.153, N.154, K.165, Y.167
Ligand excluded by PLIPNAG.32: 4 residues within 4Å:- Chain A: E.277, N.278, T.280, N.281
Ligand excluded by PLIPNAG.33: 4 residues within 4Å:- Chain A: T.373, N.387, S.389
- Ligands: NAG.34
Ligand excluded by PLIPNAG.34: 5 residues within 4Å:- Chain A: N.364, S.365, G.367, T.373
- Ligands: NAG.33
Ligand excluded by PLIPNAG.35: 5 residues within 4Å:- Chain A: C.133, T.134, N.135, K.149, Y.193
Ligand excluded by PLIPNAG.36: 4 residues within 4Å:- Chain A: E.270, E.271, N.291, E.292
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain A: A.337, N.340
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Chain A: N.356
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain A: S.389, G.390, N.393
Ligand excluded by PLIPNAG.40: 6 residues within 4Å:- Chain B: K.129, E.130, I.131, S.132, N.133, Y.134
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain B: N.114, S.116, E.117
Ligand excluded by PLIPNAG.42: 4 residues within 4Å:- Chain B: P.105, W.106, N.107, S.109
Ligand excluded by PLIPNAG.43: 5 residues within 4Å:- Chain C: S.152, F.153, N.154, K.165, Y.167
Ligand excluded by PLIPNAG.44: 4 residues within 4Å:- Chain C: E.277, N.278, T.280, N.281
Ligand excluded by PLIPNAG.45: 4 residues within 4Å:- Chain C: T.373, N.387, S.389
- Ligands: NAG.46
Ligand excluded by PLIPNAG.46: 5 residues within 4Å:- Chain C: N.364, S.365, G.367, T.373
- Ligands: NAG.45
Ligand excluded by PLIPNAG.47: 5 residues within 4Å:- Chain C: C.133, T.134, N.135, K.149, Y.193
Ligand excluded by PLIPNAG.48: 4 residues within 4Å:- Chain C: E.270, E.271, N.291, E.292
Ligand excluded by PLIPNAG.49: 2 residues within 4Å:- Chain C: A.337, N.340
Ligand excluded by PLIPNAG.50: 1 residues within 4Å:- Chain C: N.356
Ligand excluded by PLIPNAG.51: 3 residues within 4Å:- Chain C: S.389, G.390, N.393
Ligand excluded by PLIPNAG.52: 6 residues within 4Å:- Chain D: K.129, E.130, I.131, S.132, N.133, Y.134
Ligand excluded by PLIPNAG.53: 3 residues within 4Å:- Chain D: N.114, S.116, E.117
Ligand excluded by PLIPNAG.54: 4 residues within 4Å:- Chain D: P.105, W.106, N.107, S.109
Ligand excluded by PLIPNAG.55: 5 residues within 4Å:- Chain E: S.152, F.153, N.154, K.165, Y.167
Ligand excluded by PLIPNAG.56: 4 residues within 4Å:- Chain E: E.277, N.278, T.280, N.281
Ligand excluded by PLIPNAG.57: 4 residues within 4Å:- Chain E: T.373, N.387, S.389
- Ligands: NAG.58
Ligand excluded by PLIPNAG.58: 5 residues within 4Å:- Chain E: N.364, S.365, G.367, T.373
- Ligands: NAG.57
Ligand excluded by PLIPNAG.59: 5 residues within 4Å:- Chain E: C.133, T.134, N.135, K.149, Y.193
Ligand excluded by PLIPNAG.60: 4 residues within 4Å:- Chain E: E.270, E.271, N.291, E.292
Ligand excluded by PLIPNAG.61: 2 residues within 4Å:- Chain E: A.337, N.340
Ligand excluded by PLIPNAG.62: 1 residues within 4Å:- Chain E: N.356
Ligand excluded by PLIPNAG.63: 3 residues within 4Å:- Chain E: S.389, G.390, N.393
Ligand excluded by PLIPNAG.64: 6 residues within 4Å:- Chain F: K.129, E.130, I.131, S.132, N.133, Y.134
Ligand excluded by PLIPNAG.65: 3 residues within 4Å:- Chain F: N.114, S.116, E.117
Ligand excluded by PLIPNAG.66: 4 residues within 4Å:- Chain F: P.105, W.106, N.107, S.109
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Martin, J.T. et al., Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. NPJ Vaccines (2020)
- Release Date
- 2020-08-12
- Peptides
- BG505 SOSIP.v5.2(7S) - gp120: ACE
BG505 SOSIP.v5.2(7S) - gp41: BDF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
CC
AE
EB
DD
BF
F
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 27 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 36 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Martin, J.T. et al., Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. NPJ Vaccines (2020)
- Release Date
- 2020-08-12
- Peptides
- BG505 SOSIP.v5.2(7S) - gp120: ACE
BG505 SOSIP.v5.2(7S) - gp41: BDF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
CC
AE
EB
DD
BF
F